COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
17/11/2025
NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
17/11/2025
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the [...]
Apyx Medical Corporation Announces Proposed Public Offering of Common Stock
17/11/2025
CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring [...]
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
17/11/2025
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare [...]
LifeMD Reports Third Quarter 2025 Results
17/11/2025
Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million. [...]
Tilray Brands Publishes New Investor Presentation Highlighting Leadership Across Beverage, Cannabis and Wellness Industries, Showcasing Its Global Growth Strategy and Transformation into a Diversified CPG Powerhouse Shaping the Future of Consumer Products
17/11/2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands”, “Tilray” or “the Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the [...]
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
17/11/2025
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of [...]
Invivyd Announces Proposed Public Offering of Common Stock
17/11/2025
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd [...]
Kraig Biocraft Laboratories Fulfilling Order for Customized Spider Silk Application from Leading Performance Sports Brand
17/11/2025
Company to deliver spider silk yarns for elite-tier athletic application ANN ARBOR, Mich., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in [...]
Protext Mobility, Inc. (OTC: TXTM) Announces Strategic TruLeaf Partnership & Next-Level Innovation
17/11/2025
FORT LAUDERDALE, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“Protext” or the “Company”) is proud to announce a strategic Letter of Intent (LOI) with TruLeaf, marking a pivotal moment in [...]
Neocis Unveils Next-Generation AI-Powered Robotic System for Dental Implants
17/11/2025
Yomi® S and YomiPlan® AI Platform Now FDA-Cleared, Offering Unprecedented Precision, Efficiency, and Access for Dentists and Patients MIAMI, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Neocis ® , the pioneer behind the first and [...]
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
17/11/2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH) , a clinical-stage biotechnology company developing an innovative research platform based [...]
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
17/11/2025
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer NANTES, France, [...]
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedopi® dans le cancer du poumon non à petites cellules
17/11/2025
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedopi® dans le cancer du poumon non à petites cellules NANTES, le [...]
New therapeutic approach to facilitate healing of bed sores
17/11/2025
Researchers from UBC and Vancouver Coastal Health are developing natural plant compounds into a healing gel that could speed up recovery and prevent wounds from returning VANCOUVER, British Columbia, Nov. 17, 2025 ( [...]
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
17/11/2025
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of [...]
Vital Nutrients Releases Clinical Findings Showing Plant-Based Cortisol Balance Improves Sleep, Mood, and Stress Response
17/11/2025
MIDDLETOWN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Vital Nutrients , a leading practitioner-founded nutritional supplement company, has released new research highlighting the potential benefits of Cortisol Balance , a [...]
FDA Grants Fast Track Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
17/11/2025
FDA grants Fast Track designation to DPTX3186, Dewpoint’s first in class condensate modulator for gastric cancer Designation provides increased FDA engagement, rolling review eligibility, and potential for accelerated [...]
Positron Corporation Announces Its Transition to a Reporting SEC Company
17/11/2025
Buffalo, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced that it has become a reporting [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.